Management of Systemic-Sclerosis-Associated Interstitial Lung Disease

Rheumatic Disease Clinics of North America

Volumn 41, Issue 3, 2015, Pages 439-457

  Silver, Katherine Culp ^a   Silver, Richard M ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cyclophosphamide; Interstitial lung disease (ILD); Rituximab; Stem cell transplant; Systemic sclerosis (SSc)

Indexed keywords

ABATACEPT; AZATHIOPRINE; BELIMUMAB; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; MYCOPHENOLATE MOFETIL; PLACEBO; RITUXIMAB; THYMOCYTE ANTIBODY; TOCILIZUMAB; IMMUNOSUPPRESSIVE AGENT;

ADAPTIVE IMMUNITY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; EARLY DIAGNOSIS; ESOPHAGEAL PH MONITORING; GASTROESOPHAGEAL REFLUX; GENETIC POLYMORPHISM; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INNATE IMMUNITY; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG TRANSPLANTATION; MOLECULAR PATHOLOGY; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PATHOGENESIS; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PULMONARY REHABILITATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SURVIVAL RATE; SYSTEMIC SCLEROSIS; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WHOLE BODY RADIATION; COMPLICATION; FEMALE; LUNG DISEASES, INTERSTITIAL; MALE; X-RAY COMPUTED TOMOGRAPHY;

FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; MALE; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84937976482     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2015.04.006     Document Type: Review

References (68)

1. Steen V.D., Medsger T.A. Changes in causes of death in systemic sclerosis. Ann Rheum Dis 2007, 66:940-944.
2. Tyndal A.J., Banert B., Vonk M., et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010, 69:1809-1815.
3. Herzog E.L., Mathur A., Tager A.M., et al. Interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis. How similar and distinct?. Arthritis Rheum 2014, 66:1967-1978.
4. Hsu E., Shi H., Jordan R.M., et al. Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum 2011, 63:783-794.
5. Christmann R.B., Sampaio-Barros P., Stifano G., et al. Association of interferon- and transforming growth factor-β-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis. Arthritis Rheum 2014, 66:714-725.
6. Lindahl G.E., Stock C.J., Shi-Wen X., et al. Microarray profiling reveals suppressed interferon stimulated gene program in fibroblasts from scleroderma-associated interstitial lung disease. Respir Res 2013, 14:80.
7. van Bon L., Affandi A.J., Broen J., et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med 2014, 370:433-443.
8. Assassi S., Radstake T.R., Mayes M.D., et al. Genetics of scleroderma: implications for personalized medicine?. BMC Med 2013, 11:9.
9. Silver R.M., Feghali-Bostwick C. Molecular insights into systemic sclerosis-associated interstitial lung disease. Arthritis Rheum 2014, 66:485-487.
10. Ferri C., Valentini G., Cozzi F., et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002, 81(2):139-153.
11. Hant F.N., Herpel L.B., Silver R.M. Pulmonary manifestations of scleroderma and mixed connective tissue disease. Clin Chest Med 2010, 31(3):433-449.
12. Varga J. Systemic sclerosis: an update. Bull NYU Hosp Jt Dis 2008, 66(3):198-202.
13. Behr J., Furst D.E. Pulmonary function tests. Rheumatology (Oxford) 2008, 47(Suppl 5):v65-v67.
14. Silver R.M., Bogatkevich G., Tourkina E., et al. Racial differences between blacks and whites with systemic sclerosis. Curr Opin Rheumatol 2012, 24(6):642-648.
15. Steen V., Domsic R.T., Lucas M., et al. A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis. Arthritis Rheum 2012, 64:2986-2994.
16. Walker U.A., Tyndall A., Czirják L., et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research Group database. Ann Rheum Dis 2007, 66:754-763.
17. Briggs D.C., Vaughan R.W., Welsh K.I., et al. Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet 1991, 338(8768):661-662.
18. Morgan C., Knight C., Lunt M., et al. Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis 2003, 62:146-150.
19. Bouros D., Wells A.U., Nicholson A.G., et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002, 165:1581-1586.
20. Goh N.S., Desai S.R., Veeraraghavan S., et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008, 177:1248-1254.
21. Tashkin D., Elashoff R., Clements P., et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006, 25(354):2655-2666.
22. Savarino E., Bazzica M., Zentilin P., et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med 2009, 179:408-413.
23. Christmann R.B., Wells A.U., Capelozzi V.L., et al. Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence. Semin Arthritis Rheum 2010, 40(3):241-249.
24. Hant F.N., Ludwicka-Bradley A., Wang H.J., Scleroderma Lung Study Research Group, et al. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. J Rheumatol 2009, 36:773-780.
25. Yanaba K., Hasegawa M., Hamaguchi Y., et al. Longitudinal analysis of serum KL-6 levels in patients with systemic sclerosis: association with the activity of pulmonary fibrosis. Clin Exp Rheumatol 2003, 21:429-436.
26. Kodera M., Hasegawa M., Komura K., et al. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis. Arthritis Rheum 2005, 52:2889-2896.
27. Fan M.H., Feghali-Bostwick C.A., Silver R.M. Update on scleroderma-associated interstitial lung disease. Curr Opin Rheumatol 2014, 26:630-636.
28. De Laurentis A., Sestini P., Pantelidis P., et al. Serum interleukin-6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol 2013, 40:435-446.
29. Lee C.G., Herzog E.L., Ahangari F., et al. Chitinase 1 is a biomarker for and therapeutic target in scleroderma-associated interstitial lung disease that augments TGF-β signaling. J Immunol 2012, 189:2635-2644.
30. Au K., Khanna D., Clements P.J., et al. Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials. Curr Rheumatol Rep 2009, 11:111-119.
31. Tashkin D.P., Elashoff R., Clements P.J., et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007, 176:1026-1034.
32. Goldin J.G., Lynch D.A., Strollo D.C., et al. Follow-up HRCT after treatment of scleroderma-interstitial lung disease with cyclophosphamide demonstrates evidence for treatment effect. Am J Respir Crit Care Med 2008, 177(A768):91.
33. Roth M.D., Tseng C.H., Clements P.J., et al. Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis Rheum 2011, 63(9):2797-2808.
34. Hoyles R.K., Ellis R.W., Wellsbury J., et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006, 54:3962-3970.
35. Kowal-Bielecka O., Landewe R., Avouac J., et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009, 60:620-628.
36. Walker K.M., Pope J., Participating members of the Scleroderma Clinical Trials Consortium (SCTC), Canadian Scleroderma Research Group (CSRG) Treatment of systemic sclerosis complications: what to use when first-line treatment fails--a consensus of systemic sclerosis experts. Semin Arthritis Rheum 2012, 42:42-55.
37. Mittoo S., Wigley F.M., Wise R.A., et al. Long term effects of cyclophosphamide treatment on lung function and survival in scleroderma patients with interstitial lung disease. Open Rheumatol J 2011, 5:1-6.
38. Swigris J.J., Olson A.L., Fischer A., et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 2006, 130:30-36.
39. Liossis S.N., Bounas A., Andonopoulos A.P. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford) 2006, 45:1005-1008.
40. Nihtyanova S.I., Brough G.M., Black C.M., et al. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis - a retrospective analysis. Rheumatology (Oxford) 2007, 46:442-445.
41. Zamora A.C., Wolters P.J., Collard H.R., et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med 2008, 102:150-155.
42. Gerbino A.J., Goss C.H., Molitor J.A. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 2008, 133:455-460.
43. Derk C.T., Grace E., Shenin M., et al. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology 2009, 48:1595-1599.
44. Koutroumpas A., Ziogas A., Alexiou I., et al. Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol 2010, 29:1167-1168.
45. Le E.N., Wigley F.M., Shah A.A., et al. Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2011, 70:1104-1107.
46. Simeon-Aznar C.P., Fonollosa-Pia V., Tolosa-Vilella C., et al. Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. Clin Rheumatol 2011, 30:1393-1398.
47. Mendoza F.A., Nagle S.J., Lee J.B., et al. A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheumatol 2012, 39:1241-1247.
48. Henes J.C., Horger M., Amberger C., et al. Enteric-coated mycophenolate sodium for progressive systemic sclerosis - a prospective open-label study with CT histography for monitoring pulmonary fibrosis. Clin Rheumatol 2013, 32:673-678.
49. Panopoulos S.T., Bournia V.K., Trakada G., et al. Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study. Lung 2013, 191:483-489.
50. Nadashkevich O., Davis P., Fritzler M., et al. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 2006, 25:205-212.
51. Daoussis D., Liossis S.N., Tsamandas A.C., et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 2010, 49:271-280.
52. Jordan S., Distler J.H., Maurer B., On behalf of the EUSTAR rituximab study group, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 2014, 10.1136/annrheumdis-2013-204522.
53. Van Laar J.M., Farge D., Sont J.K., EBMT/EULAR Scleroderma Study Group, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis. A randomized clinical trial. JAMA 2014, 311:2490-2498.
54. Burt R.K., Shah S.J., Dill K., et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomized phase 2 trial. Lancet 2011, 378:498-506.
55. Wynn T.A. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 2007, 117:524-529.
56. Antonelli A., Ferri C., Ferrari S.M., et al. Peroxisome proliferator-activated receptor γ agonists reduce cell proliferation and viability and increase apoptosis in systemic sclerosis fibroblasts. Br J Dermatol 2013, 168(1):129-135.
57. Bogatkevich G.S., Highland K.B., Akter T., et al. The PPARγ agonist rosiglitazone is antifibrotic for scleroderma lung fibroblasts: mechanisms of action and differential racial effects. Pulm Med 2012, 2012:545172.
58. Wei J., Ghosh A.K., Sargent J.L., et al. PPARγ downregulation by TGFβ in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLoS One 2010, 5(11):e13778.
59. Timár O., Szekanecz Z., Kerekes G., et al. Rosuvastatin improves impaired endothelial function, lowers high sensitivity CRP, complement and immuncomplex production in patients with systemic sclerosis-a prospective case-series study. Arthritis Res Ther 2013, 15:R105.
60. Ruben E.C., Manuel V.R., Agustin O.R., et al. Ciprofloxacin utility as antifibrotic in the skin of patients with scleroderma. J Dermatol 2010, 37:323-329.
61. Atanelishvili I., Liang J., Akter T., et al. Thrombin increases lung fibroblast survival while promoting alveolar epithelial cell apoptosis via the endoplasmic reticulum stress marker, CCAAT enhancer-binding homologous protein. Am J Respir Cell Mol Biol 2014, 50:893-902.
62. Rosenbloom J., Mendoza F.A., Jimenez S.A. Strategies for anti-fibrotic therapies. Biochim Biophys Acta 2013, 1832:1088-1103.
63. Suzuki Y., Hayakawa H., Miwa S., et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung 2009, 187(3):201-206.
64. De Cruz S., Ross D. Lung transplantation in patients with scleroderma. Curr Opin Rheumatol 2013, 25:714-718.
65. Shitrit D., Amitai A., Peled N., et al. Lung transplantation in patients with scleroderma: case series, review of the literature, and criteria for transplantation. Clin Transplant 2009, 23:178-183.
66. Schachna L., Medsger T.A., Dauber J.H., et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum 2006, 54:3954-3961.
67. Khan I.Y., Singer L.G., de Perrot M., et al. Survival after lung transplantation in systemic sclerosis. A systematic review. Respir Med 2013, 107:2081-2087.
68. Fisichella P.M., Reder N.P., Gagermeier J., et al. Usefulness of pH monitoring in predicting the survival status of patients with scleroderma awaiting lung transplantation. J Surg Res 2014, 189:232-237.